Coya Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 16, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 16, 2026

COYA$3.16-5.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2025 and 2024

BALANCE SHEETS

	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$46,822,786	$38,339,762
Prepaids and other current assets	3,116,232	5,968,666
Total current assets	49,939,018	44,308,428
Fixed assets, net	11,227	38,588
Total assets	$49,950,245	$44,347,016
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$1,061,122	$1,588,128
Accrued expenses	3,612,913	1,388,060
Deferred collaboration revenue	1,197,856	848,286
Total current liabilities	5,871,891	3,824,474
Deferred collaboration revenue	1,050,124	945,447
Total liabilities	6,922,015	4,769,921
Commitments and contingencies (Note 6)
Stockholders' equity:
Series A convertible preferred stock, $0.0001 par value: 10,000,000 shares authorized, none issued and outstanding as of December 31, 2025 and 2024	-	-
Common stock, $0.0001 par value; 200,000,000 shares authorized; 20,934,456 and 16,707,441 shares issued and outstanding as of December 31, 2025 and 2024, respectively	2,094	1,671
Additional paid-in capital	104,989,413	80,312,594
Accumulated deficit	(61,963,277)	(40,737,170)
Total stockholders' equity	43,028,230	39,577,095
Total liabilities and stockholders' equity	$49,950,245	$44,347,016

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.